Lv1
28 积分 2025-06-10 加入
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study
6个月前
已完结
Expanding Access to Cancer Immunotherapy: A Systematic Review of Low-Dose PD-(L)1 Inhibitor Strategies
7个月前
已完结
783 SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors
7个月前
已完结
Conversion of vaccines from low to high immunogenicity by antibodies with epitope complementarity
9个月前
已完结
皖公网安备34019202002308
